Sixfold Bioscience (Sixfold), a company harnessing computation and advanced chemistry to design RNA therapeutic delivery systems, today announced it has raised a total of $10.5 million USD (£7.8 million GBP) in its seed funding round. The funding will support the continued development of the Company’s Mergo® RNA therapeutics delivery platform.

hC Bioscience is dedicated to improving the lives of patients with the development of first-in-class tRNA-based therapeutics targeting protein dysfunction. hC’s innovations in precision protein editing therapies target genetically defined diseases.  A single tRNA therapy has the potential to treat many diseases, regardless of the gene or location of the mutation.  

Sixfold Bioscience Completes $10.5M Usd (£7.8M Gbp) Seed Financing

Description

Company Information

Related People

Funding Insights